Study identifier:D5130C00131
ClinicalTrials.gov identifier:NCT02185534
EudraCT identifier:N/A
CTIS identifier:N/A
An open-label, randomised, three-way crossover study in healthy subjects to assess the bioequivalence of European source generic clopidogrel tablets and US and Japanese source branded clopidogrel (Plavix®) tablets.
Bioequivalence, AUC, Cmax, Pharmacokinetics
Phase 1
Yes
Clopidogrel
All
144
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 May 2016 by AstraZeneca
AstraZeneca
-
This study will be an open-label, randomised, three-way crossover study in healthy male and female subjects, performed at a single centre. The objective of the study is to assess the bioequivalence between one test formulation (Clopidogrel 75 mg tablet (commercial blister from KRKA) and two reference formulations (Clopidogrel 75 mg tablet [Plavix, sourced in US and Japan]).
Study to evaluate the bioequivalence of orally administered European source clopidogrel tablets and US and Japanese source clopidogrel tablets.
Location
Location
Berlin, Germany
Arms | Assigned Interventions |
---|---|
Experimental: European clopidogrel tablets, 75 mg Treatment A: a single oral dose of clopidogrel 75 mg film-coated tablet (Zyllt, KRKA - test) | Drug: Clopidogrel European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference) Other Name: Zyllt Other Name: Plavix |
Active Comparator: Japanese clopidogrel tablets, 75 mg Treatment B: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Brystol-Myer Squibb,Sanofi-Aventis, reference) | Drug: Clopidogrel European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference) Other Name: Zyllt Other Name: Plavix |
Active Comparator: US clopidogrel tablets, 75 mg Treatment C: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Sanofi-Aventis, reference) | Drug: Clopidogrel European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference) Other Name: Zyllt Other Name: Plavix |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.